Maravai LifeSciences currently holds 589.52
M in liabilities with Debt to Equity (D/E) ratio of 2.81, implying Maravai LifeSciences greatly relies on financing operations through barrowing.
The company secures a Beta (Market Risk) of -0.7893, which conveys possible diversification benefits within a given portfolio. Let's try to break down what Maravai's beta means in this case. As returns on the market increase, returns on owning Maravai LifeSciences are expected to decrease at a much lower rate. During the bear market, Maravai LifeSciences is likely to outperform the market. Even though it is essential to pay attention to
Maravai LifeSciences price patterns, it is always good to be careful when utilizing equity historical
price patterns. Our philosophy towards estimating any stock's
future performance is to check both, its past performance charts as well as the business as a whole, including all available
technical indicators. Maravai LifeSciences exposes twenty-eight different technical indicators, which can help you to evaluate its performance.
Maravai LifeSciences has an expected return of -0.46%. Please be advised to verify Maravai LifeSciences Holdings
value at risk, as well as the
relationship between the skewness and
day median price to decide if
Maravai LifeSciences performance from the past will be repeated at some point in the near future.
Maravai Lifesciences financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Maravai Lifesciences, including all of Maravai Lifesciences's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Maravai Lifesciences assets, the company is considered highly leveraged. Understanding the
composition and structure of overall Maravai Lifesciences debt and outstanding corporate bonds gives a good idea of
how risky the capital structure of a business is and if it is worth investing in it. Please read more on our
technical analysis page.
Understanding Maravai Total Debt
Maravai Lifesciences liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Maravai Lifesciences has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Maravai Lifesciences balance sheet include debt obligations and money owed to different Maravai Lifesciences vendors, workers, and loan providers. Below is the chart of Maravai main long-term debt accounts currently reported on its balance sheet.
You can use Maravai Lifesciences HoldingsInc
financial leverage analysis tool to get a better grip on understanding its financial position
How important is Maravai Lifesciences's Liquidity
Maravai Lifesciences
financial leverage refers to using borrowed capital as a funding source to finance Maravai Lifesciences HoldingsInc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Maravai Lifesciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Maravai Lifesciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Maravai Lifesciences' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Maravai Lifesciences's total debt and its cash.
Another angle On Maravai Lifesciences
This firm reported the previous year's revenue of 381.33
M. Net Income was 77.81
M with profit before overhead, payroll, taxes, and interest of 204.45
M.
Asset Breakdown
869.1 M
Assets Non Current
| Total Assets | 1.13 Billion |
| Current Assets | 357.78 Million |
| Assets Non Current | 869.07 Million |
| Goodwill | 389.29 Million |
| Tax Assets | 386.26 Million |
Over 3 percent rise for Maravai LifeSciences. What does it mean for stockholders?
The coefficient of variation is down to -1000.5 as of today. Maravai LifeSciences Holdings exhibits very low volatility with skewness of -1.97 and kurtosis of 8.61. However, we advise investors to further study Maravai LifeSciences Holdings technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Maravai LifeSciences' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Maravai LifeSciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Maravai LifeSciences Implied Volatility
Maravai LifeSciences' implied volatility exposes the market's sentiment of Maravai LifeSciences Holdings stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Maravai LifeSciences' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Maravai LifeSciences stock will not fluctuate a lot when Maravai LifeSciences' options are near their expiration.
Our Final Take On Maravai LifeSciences
While few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Maravai LifeSciences may offer a potential longer-term growth to stockholders. The inconsistency in the assessment between current Maravai valuation and our trade advice on Maravai LifeSciences is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Maravai LifeSciences.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Maravai Lifesciences HoldingsInc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com